Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel cinnoline-based inhibitors of LRRK2 kinase activity.

Bioorganic & medicinal chemistry letters - 1 Jan 2013

Garofalo Albert W, Adler Marc, Aubele Danielle L, Bowers Simeon, Franzini Maurizio, Goldbach Erich, Lorentzen Colin, Neitz R Jeffrey, Probst Gary D, Quinn Kevin P, Santiago Pam, Sham Hing L, Tam Danny, Truong Anh P, Ye Xiaocong M, Ren Zhao

Abstract excerpt

Leucine rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of cinnoline-3-carboxamides that are potent ag...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to HEK293 Cells
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to Protein Structure, Tertiary

Share to Transfection

Source

Identifiers

PMID: 23219325
DOI: 10.1016/j.bmcl.2012.11.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23219325-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel cinnoline-based inhibitors of LRRK2 kinase activity.PMID 23219325Read ↗

Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.Semantic proximity Read ↗

Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.Semantic proximity Read ↗

Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read ↗

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.Semantic proximity Read ↗

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.Semantic proximity Read ↗

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule InhibitorsSemantic proximity Read ↗

A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read ↗

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.